ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Implications of COVID-19 on statistical design and analyses of clinical studies
Tim Victor, Head of Biostatistics at ICON, considers the challenges and risks to statistical integrity and how they can be mitigated.
ICON: What a difference a year makes as sales jump and PRA Health integration begins
In its first-quarter results, ICON saw revenue hit $858 million, up 17.9% on a constant currency basis on the year-ago period, with full-year 2021 revenue guidance boosted from a range of $3.2 billion to $3.3 billion to as much as $3.5 billion.
Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
How will NICE fare in a post-Brexit world?
In this article, ICON experts Caroline Delaitre-Bonnin, Emmanuel Lacharme and Manpreet Sidhu, consider how the UK drug pricing group, NICE, will be impacted post-Brexit.
Data Science: transforming the future of clinical trials
Gerard Quinn, VP of IT Innovation & Informatics, offers insights on the use of Machine Learning and Artificial Intelligence in clinical trials, and the potential benefits and challenges for CROs and sponsors.
Real world evidence and the patient experience: Involving rare disease patients for successful trials
ICON's William C Maier and Maggie Adamski consider how real world evidence can support those suffering with rare diseases around the world.
Two key questions about payer strategies in 2021
An interview with market access experts, including ICON's John Sliwka, on what they expect to see changing in the payer landscape in the coming years in the US market with the new Biden administration taking place.
Patient centricity vital to advancing rare disease treatments: ICON
Benoit Arnould, Director of Patient Centred Outcomes at ICON discusses how putting the patient first in clinical research is essential to discovering new therapies for orphan diseases.
Proving long-term value in advanced therapies: Digital technologies can measure durability of effect
This article by Marie McCarthy and Bob Swann discusses how robust assessments based on digital data are a means of reducing the uncertainty that HTA bodies and payers face in making decisions around advanced therapy medicinal products.
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.